• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia Technologies

1.19 EUR-2.30 %24.7, 17.29
2,225 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-2.30 %
-34.00 %
-31.72 %
-47.20 %
-52.29 %
-63.56 %
-72.63 %
-
-76.52 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
44.42M EUR
Turnover
178.42K EUR
P/E (adj.) (26e)
-4.07
EV/EBIT (adj.) (26e)
-4.32
P/B (26e)
3.33
EV/S (26e)
15.6
Dividend yield-% (26e)
-
Coverage
Recommendation
Reduce
Target price
1.30 EUR
Updated
22.07.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 23.07.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Hi Jukka. We certainly all appreciate you reaching out to us retail investors in this situation. I, and I believe many other investors, have assumed that with a SaaS revenue model, and as new contracts have slowly accumulated—especially if you haven’t lost any clinical customers—...
7/23/2026, 7:39 PM
by JusaVaan
25
Small acquisition by the CEO Inderes Aiforia Technologies Oyj – Johdon liiketoimet – Jukka Tapaninen - Inderes Aiforia Technologies Oyj, Yhtiötiedote, Johtohenkilöiden liiketoimet 24.7.2026 klo 11.00 Aiforia Technologies Oyj – Johdon liiketoimet – Jukka Tapaninen___________________________...
7/24/2026, 8:11 AM
by Saku
21
This important and politely presented question from Jussi remains unanswered. I am also wondering what information was given to those who participated in last month’s directed share issue regarding the development of revenue at that time. They likely didn’t have information about...
10 hours ago
15
A few observations. At least here in Finland, in public tenders, the contracting entity does not commit to any specific order volumes from suppliers – and this also applies to the Fimlab case. This is based on a framework agreement under which Fimlab can purchase services from Aiforia...
7/24/2026, 9:36 AM
by Matti
14
Well, that really just depends on what on earth is happening at the company—whether something positive is also going on, or if it’s just a total collapse in revenue growth. Hopefully, the firm communicates more soon. It has certainly looked bad so far. On the other hand, the insiders...
7/24/2026, 8:02 PM
by JusaVaan
7
I would agree with this if it weren’t clearly a so-called once-a-year practice, as it is now.
7/24/2026, 12:07 PM
by Perttu Hämäläinen
6
I wonder if there is also a broader rollout brewing in the UK. Some Vice President of Global Industry Marketing at Microsoft is sharing a link to a Microsoft partner blog about the Aiforia/UK case. The blog discusses a wider NHS deployment in the UK (the blog is from a month ago)...
7/24/2026, 9:36 AM
by Puutaheinää
6
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.8
2026

Interim report Q2'26

Regulatory press release24.07.2026, 10.00

Aiforia Technologies Plc – Managers’ Transactions – Jukka Tapaninen

Aiforia Technologies
Third party research23.07.2026, 09.04

Aiforia Technologies: Aiforia H1 profit warning triggers downgrade to HOLD - NuWays AG Research

Aiforia issued a profit warning with H1'26 revenues coming in at a mere € 0.75m, down from € 1.4m in H1'25 (-46% yoy), against our expectation of roughly doubling yoy, following last year's strong Clinical momentum (organic growth of +65%). At the same...

Aiforia Technologies
Aiforia: We diagnose a growth deficiency
Research23.07.2026, 09.25 by
Antti Siltanen

Aiforia: We diagnose a growth deficiency

The ongoing uncertainty regarding growth is causing us to take a negative view of the risk-reward ratio.

Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Aiforia's H1 revenue was surprisingly subdued
Analyst Comment22.07.2026, 08.05 by
Antti Siltanen

Aiforia's H1 revenue was surprisingly subdued

The conversion of customer wins into revenue continues to be slow.

Aiforia Technologies
Regulatory press release21.07.2026, 17.40

Inside information, profit warning: Aiforia's revenue developed below the estimates during January–June 2026

Aiforia Technologies
Regulatory press release06.07.2026, 08.00

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release06.07.2026, 08.00

Aiforia Technologies Plc – Managers’ Transactions – Johan Lundin

Aiforia Technologies
Regulatory press release01.07.2026, 20.00

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act (Acme Investments SPF Sarl)

Aiforia Technologies
Third party research29.06.2026, 09.21

Aiforia Technologies: € 6.4m share issue de-risks the investment case - NuWays AG Research

On Thursday evening, Aiforia announced having completed a directed share issue of 3.6m shares at € 1.772 per share, raising gross proceeds of some € 6.4m. The subscription price corresponds to the closing price of June 25th, representing no discount ...

Aiforia Technologies
Regulatory press release26.06.2026, 15.30

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release26.06.2026, 15.20

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act (Tuomas Tenkanen/TJT Technologies Oy)

Aiforia Technologies
Regulatory press release26.06.2026, 11.15

A total of 3,600,000 new shares in Aiforia Technologies Plc registered with the Trade Register

Aiforia Technologies
Aiforia collects 6.4 MEUR in a directed share issue
Analyst Comment26.06.2026, 07.49 by
Antti Siltanen

Aiforia collects 6.4 MEUR in a directed share issue

The company's financial risk in the coming years will diminish if the planned EIB loan materializes in addition to the share issue.

Aiforia Technologies
Regulatory press release25.06.2026, 21.00

Inside information: Aiforia Technologies Plc successfully completes a directed share issue raising approximately EUR 6.4 million

Aiforia Technologies
Regulatory press release25.06.2026, 17.31

Inside information: Aiforia Technologies Plc intends to carry out a directed share issue by means of an accelerated bookbuilding process

Aiforia Technologies
Third party research17.06.2026, 08.21

Aiforia Technologies: €20m EIB debt term sheet de-risks Aiforia's funding outlook - NuWays AG Research

Aiforia agrees non-binding EIB term sheet for up to €20m venture debt, materially de-risking the funding outlook. BUY, PT €3.80 unchanged.

Aiforia Technologies
Aiforia indicatively agreed on a 20 MEUR financing facility with the EIB
Analyst Comment16.06.2026, 08.16 by
Antti Siltanen, Antti Luiro

Aiforia indicatively agreed on a 20 MEUR financing facility with the EIB

The financing package would significantly reduce the short-term financing risk.

Aiforia Technologies
Regulatory press release15.06.2026, 20.45

Inside information: Aiforia and the European Investment Bank agree upon a non-binding indicative term sheet for an up to EUR 20 million venture debt financing facility

Aiforia Technologies
Aiforia expands to nine hospitals in Spain
Analyst Comment12.06.2026, 08.26 by
Antti Siltanen

Aiforia expands to nine hospitals in Spain

The news continues Aiforia's series of gradual growth steps with 9 new hospitals.

Aiforia Technologies
Press release11.06.2026, 08.30

Aiforia expands its presence in Spain through a new clinical account

Aiforia Technologies